# Zasocitinib PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/zasocitinib

> The PDUFA target action date for zasocitinib, sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), is Q1 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | zasocitinib |
| Codes | TAK-279, NDI-034858 |
| Sponsor | TAKEDA PHARMACEUTICAL CO LTD (TAK) https://sec-api.dev/companies/tak/catalysts |
| Indications | [moderate-to-severe plaque psoriasis](https://sec-api.dev/indications/moderate-to-severe-plaque-psoriasis), with moderate-to-severe plaque psoriasis, [Psoriatic Arthritis](https://sec-api.dev/indications/psoriatic-arthritis), [Nonsegmental Vitiligo](https://sec-api.dev/indications/nonsegmental-vitiligo), [Ulcerative Colitis](https://sec-api.dev/indications/ulcerative-colitis), [Crohn's Disease](https://sec-api.dev/indications/crohn-s-disease), [Palmoplantar Psoriasis](https://sec-api.dev/indications/palmoplantar-psoriasis), [Plaque Psoriasis](https://sec-api.dev/indications/plaque-psoriasis) |
| Modality | small_molecule |
| FDA designations | priority review |

## Timeline

### December 18, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3. Indication: moderate-to-severe plaque psoriasis.
- First seen 2025-12-18, last confirmed 2026-06-17.
- SEC Form 10-K (accession 0001395064-26-000177): "-In December 2025, Takeda announced positive topline results for two pivotal Phase 3 studies of zasocitinib in adults with moderate-to-severe plaque psoriasis (PsO)." https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm
- SEC Form 8-K (accession 0001395064-25-000174): "OSAKA Japan AND CAMBRIDGE, Massachusetts, December 18, 2025 - Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the two pivotal Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO)." https://www.sec.gov/Archives/edgar/data/1395064/000139506425000174/form6k_121825.htm
- Press release filed with the SEC (EX-99) (accession 0001395064-26-000162): "Development code: TAK-279 / Generic name: zasocitinib - In December 2025, Takeda announced positive topline results for two pivotal Phase 3 studies of zasocitinib in adults with moderate-to-severe plaque psoriasis (PsO)." https://www.sec.gov/Archives/edgar/data/1395064/000139506426000162/noticeofconvocationofthe.htm

### April 22, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Plaque Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06973291 (A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-22 (ACTUAL); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06973291

### July 14, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Ulcerative Colitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06254950 (A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-07-14 (ACTUAL); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06254950

### Sep 2026: NDA/BLA acceptance

- Status: completed. Date confidence: month. Indication: with moderate-to-severe plaque psoriasis.
- First seen 2026-10-29, last confirmed 2026-10-29.
- SEC Form 8-K (accession 0001395064-26-000345): "-In September 2026, Takeda announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib for the treatment of adults with moderate-to-severe plaque psoriasis." https://www.sec.gov/Archives/edgar/data/1395064/000139506426000345/form6k-2_102926.htm

### Q1 2027: PDUFA date

- Status: scheduled. Date confidence: quarter.
- First seen 2026-09-14, last confirmed 2026-10-29.
- SEC Form 8-K (accession 0001395064-26-000337): "•The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027" https://www.sec.gov/Archives/edgar/data/1395064/000139506426000337/form6k_091426.htm
- SEC Form 8-K (accession 0001395064-26-000345): "The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the first quarter of calendar year 2027." https://www.sec.gov/Archives/edgar/data/1395064/000139506426000345/form6k-2_102926.htm

### Feb to May 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06233461 (A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-17 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06233461

### February 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06233461 (A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-17 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06233461

### Mar to Jun 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Nonsegmental Vitiligo.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07108283 (A Study of Zasocitinib in Adults With Nonsegmental Vitiligo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-26 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07108283

### March 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Nonsegmental Vitiligo.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07108283 (A Study of Zasocitinib in Adults With Nonsegmental Vitiligo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-26 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07108283

### May to Aug 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Psoriatic Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06671483 (A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-18 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06671483

### May to Aug 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Psoriatic Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06671496 (A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-18 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06671496

### May to Aug 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Palmoplantar Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07752108 (A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-05-30 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07752108

### May 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Psoriatic Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06671483 (A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-18 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06671483

### May 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Psoriatic Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06671496 (A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-18 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06671496

### May 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Palmoplantar Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07752108 (A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-05-30 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07752108

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07403968 (A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-30 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07403968

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07403968 (A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-30 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07403968

### Dec 2029 to Mar 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Crohn's Disease; Ulcerative Colitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06764615 (A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-12-30 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06764615

### Dec 2029 to Mar 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Psoriatic Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07286058 (Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-18 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07286058

### December 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Psoriatic Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07286058 (Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-18 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07286058

### December 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Crohn's Disease; Ulcerative Colitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06764615 (A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-12-30 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06764615

### Apr to Jul 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Psoriatic Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07871721 (A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-04-18 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07871721

### April 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Psoriatic Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07871721 (A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-04-18 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07871721

## Same indication

- [ABBV-701](https://sec-api.dev/pdufa/abbv-701) (ABBV)
- [ABBV-8736](https://sec-api.dev/pdufa/abbv-8736) (ABBV)
- [ABX464](https://sec-api.dev/pdufa/abx464) (ABVX)
- [AMJEVITA® (adalimumab)](https://sec-api.dev/pdufa/adalimumab) (ABBV)
- [Otezla (apremilast)](https://sec-api.dev/pdufa/apremilast) (AMGN)
- [AZD7798](https://sec-api.dev/pdufa/azd7798) (AZN)
- [Brivekimig](https://sec-api.dev/pdufa/brivekimig) (SNY)
- [Darvadstrocel](https://sec-api.dev/pdufa/darvadstrocel) (TAK)
- [Sotyktu (deucravacitinib)](https://sec-api.dev/pdufa/deucravacitinib) (BMY)
- [Duvakitug](https://sec-api.dev/pdufa/duvakitug) (SNY)
- [Eltrekibart](https://sec-api.dev/pdufa/eltrekibart) (LLY)
- [Emvistegrast](https://sec-api.dev/pdufa/emvistegrast) (GILD)
- [Envudeucitinib](https://sec-api.dev/pdufa/envudeucitinib) (ALMS)
- [Etrasimod](https://sec-api.dev/pdufa/etrasimod) (PFE)
- [Tremfya (guselkumab)](https://sec-api.dev/pdufa/guselkumab) (JNJ)
- [Iv tulisokibart](https://sec-api.dev/pdufa/iv-tulisokibart) (MRK)
- [Taltz (ixekizumab)](https://sec-api.dev/pdufa/ixekizumab) (LLY)
- [Mirikizumab](https://sec-api.dev/pdufa/mirikizumab) (LLY)
- [Mirikizumab iv](https://sec-api.dev/pdufa/mirikizumab-iv) (LLY)
- [Nx-13 250mg](https://sec-api.dev/pdufa/nx-13) (ABBV)
- [Obefazimod](https://sec-api.dev/pdufa/obefazimod) (ABVX)
- [Open-label envudeucitinib](https://sec-api.dev/pdufa/open-label-envudeucitinib) (ALMS)
- [ORKA-001](https://sec-api.dev/pdufa/orka-001) (ORKA)
- [Orka-001 induction dose](https://sec-api.dev/pdufa/orka-001-induction-dose) (ORKA)
- [ORKA-002](https://sec-api.dev/pdufa/orka-002) (ORKA)
- [Piclidenoson](https://sec-api.dev/pdufa/piclidenoson) (CANF)
- [Skyrizi® (risankizumab)](https://sec-api.dev/pdufa/risankizumab) (ABBV)
- [Risankizumab iv](https://sec-api.dev/pdufa/risankizumab-iv) (ABBV)
- [Risankizumab sc](https://sec-api.dev/pdufa/risankizumab-sc) (ABBV)
- [SAR441566](https://sec-api.dev/pdufa/sar441566) (SNY)
- [SPY001](https://sec-api.dev/pdufa/spy001) (SYRE)
- [TAK-279](https://sec-api.dev/pdufa/tak-279) (TAK)
- [Tapinarof cream, 1%](https://sec-api.dev/pdufa/tapinarof-cream-1) (OGN)
- [Tilpisertib fosmecarbil](https://sec-api.dev/pdufa/tilpisertib-fosmecarbil) (GILD)
- [Zepbound (tirzepatide)](https://sec-api.dev/pdufa/tirzepatide) (LLY)
- [Xeljanz (tofacitinib citrate)](https://sec-api.dev/pdufa/tofacitinib) (PFE)
- [Tulisokibart](https://sec-api.dev/pdufa/tulisokibart) (MRK)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)
- [WEZLANA® (ustekinumab)](https://sec-api.dev/pdufa/ustekinumab) (JNJ)
- [Entyvio® (vedolizumab)](https://sec-api.dev/pdufa/vedolizumab) (TAK)
- [Vedolizumab iv](https://sec-api.dev/pdufa/vedolizumab-iv) (TAK)
- [Vedolizumab sc](https://sec-api.dev/pdufa/vedolizumab-sc) (TAK)
- [VYN202](https://sec-api.dev/pdufa/vyn202) (YARW)
- [Zl-1102 1% w/w gel bid for 16 weeks](https://sec-api.dev/pdufa/zl-1102-1-w-w-gel-bid-for-16-weeks) (ZLAB)
- [Zotemtegrast](https://sec-api.dev/pdufa/zotemtegrast) (LLY)

Calendar months: [February 2027](https://sec-api.dev/fda-calendar/2027-02), [March 2027](https://sec-api.dev/fda-calendar/2027-03), [May 2027](https://sec-api.dev/fda-calendar/2027-05), [March 2028](https://sec-api.dev/fda-calendar/2028-03)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/zasocitinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Zasocitinib PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/zasocitinib

```bibtex
@misc{secapidev_pdufa_zasocitinib_20261116,
  title        = {Zasocitinib PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/zasocitinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_zasocitinib_20261116","title":"Zasocitinib PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/zasocitinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
